Mercados españoles cerrados

Qiagen N.V. (QIA.DE)

XETRA - XETRA Precio demorado. Divisa en EUR
Añadir a la lista de favoritos
46,65+0,36 (+0,78%)
Al cierre: 05:35PM CEST

Qiagen N.V.

Hulsterweg 82
Venlo 5912 PL
Netherlands
31 77 355 6600
https://www.qiagen.com

Sector(es)Healthcare
SectorDiagnostics & Research
Empleados a tiempo completo6000

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Thierry BernardCEO, MD & Member of Management Board2,02MN/A1965
Dr. Roland SackersCFO, MD & Member of Management Board1,18MN/A1969
Mr. Antonio SantosSr. VP & Head of Global OperationsN/AN/AN/A
Mr. John GilardiVP of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Stephany FosterSr. VP & Head of HRN/AN/AN/A
Dr. Thomas SchweinsSr. VP of Life Science Bus. AreaN/AN/AN/A
Dr. Thomas TheuringerSr. Director & Head of External CommunicationsN/AN/AN/A
Mr. Jean-Pascal ViolaSr. VP & Head of Molecular Diagnostics Bus. AreaN/AN/AN/A
Dr. Jonathan G. Sheldon Ph.D.Sr. VP of Qiagen Digital Insights Bus. AreaN/AN/A1972
Mr. Thomas NeidertVP of Global TreasuryN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Gobierno corporativo

El ISS Governance QualityScore de Qiagen N.V., a día 1 de julio de 2022, es 5. Las puntuaciones base son Auditoría: 6; Tablero: 3; Derechos de los accionistas: 9; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.